Tag: health regulation & law

Published Articles (9)

American Journal of Bioethics: Volume 17 Issue 3 - Mar 2017

The Precautionary Principle and the Tolerability of Blood Transfusion Risks Koen Kramer, Hans L. Zaaijer & Marcel F. Verweij

AJOB Primary Research: Volume 8 Issue 1 - Feb 2017

Morals or markets? Regulating assisted reproductive technologies as morality or economic policies in the states Erin Heidt-Forsythe

AJOB Primary Research: Volume 8 Issue 1 - Feb 2017

Problematic protocols: An overview of medical research protocols not approved by the LUMC medical ethics review committee Derek Gideon Tersmette & Dirk Peter Engberts

American Journal of Bioethics: Volume 16 Issue 12 - Dec 2016

Does Lack of “Genetic-Relative Family Health History” Represent a Potentially Avoidable Health Disparity for Adoptees? Thomas May, Kimberly A. Strong, Kaija L. Zusevics, Jessica Jeruzal, Michael H. Farrell, Alison LaPean Kirschner, Arthur R. Derse, James P. Evans & Harold D. Grotevant

American Journal of Bioethics: Volume 16 Issue 11 - Nov 2016

The Ethics of Organ Donor Registration Policies: Nudges and Respect for Autonomy Douglas MacKay & Alexandra Robinson

American Journal of Bioethics: Volume 16 Issue 11 - Nov 2016

Autonomy by Default Cass R. Sunstein

American Journal of Bioethics: Volume 16 Issue 2 - Feb 2016

Fetal Risks, Relative Risks, and Relatives' Risks Howard Minkoff & Mary Faith Marshall

American Journal of Bioethics: Volume 16 Issue 2 - Feb 2016

Restricting Choices of Childbearing Women Bela Fishbeyn

American Journal of Bioethics: Volume 15 Issue 4 - Apr 2015

Kaci Hickox: Public Health and the Politics of Fear Steven H. Miles

News (39)

March 21, 2017 9:00 am

Federal advisory panels agree Opana's risks outweigh benefits (USA Today)

The new extended-release version of Endo Pharmaceuticals’ Opana may even be more dangerous than the version it replaced, according to critics including the advocacy group Public Citizen. Two Food and Drug Administration advisory panels seemed to agree, voting 18 to 8 that it presents more risks than benefits to society. Next it’s up to the FDA to decide whether to act on the panels’ advice, which it generally does. Possible actions include changes to labels, restriction of prescriptions and an outright ban.

March 13, 2017 9:00 am

Employees who decline genetic testing could face penalties under proposed bill (Washington Post)

Employers could impose hefty penalties on employees who decline to participate in genetic testing as part of workplace wellness programs if a bill approved by a U.S. House committee this week becomes law.

February 16, 2017 9:00 am

Speedy drug approvals are risky, but drug companies have another idea that's just terrible (Los Angeles Times)

As with Trump’s proposed elimination of consumer safeguards, environmental-protection measures and financial reforms, the reality is that if his administration proceeds with a wholesale deregulation of the drug industry, the public will be largely undefended against the aggressive and potentially dangerous predations of multibillion-dollar conglomerates.

February 6, 2017 9:00 am

Will the Trump presidency mean the end of FDA drug regulation? (Los Angeles Times)

Donald Trump will be coming into office waving the banner of deregulation. While most of the speculation about his plans has focused on the financial industry and the possibility of eviscerating Dodd-Frank reforms, keep your eyes on the Food and Drug Administration. In a Trump administration the agency, figuratively speaking, will have a big bull’s-eye on its back.

January 25, 2017 9:00 am

We spoke with the man who could lead the world's top health organization (Business Insider)

The WHO lost a lot of trust in the aftermath of the 2014 Ebola outbreak in West Africa. Nabarro said his hope is to make sure that doesn’t happen again.

January 24, 2017 9:00 am

With executive order, Trump tosses a ‘bomb’ into fragile health insurance markets (Washington Post)

The practical implications of Trump’s action on Friday are harder to decipher. Its language instructs all federal agencies to “waive, defer, grant ­exemptions from or delay” any part of the law that imposes a financial or regulatory burden on those affected by it. That would cover consumers, doctors, hospitals and other providers, as well as insurers and drug companies.

January 9, 2017 9:00 am

Fact-checking Congress’s fetal tissue report (Science)

They interviewed senior physicians from Planned Parenthood, who spoke bluntly about their provision of fetal tissue from legal abortions for medical research

January 5, 2017 9:00 am

After Backlash, Including From Trump, House GOP Drops Weakening Of Ethics Office (NPR)

House Republicans have reversed themselves and restored the current rules of the Office of Congressional Ethics

December 23, 2016 9:00 am

Abortion Is Found to Have Little Effect on Women’s Mental Health (The New York Times)

Some states require women seeking abortions to be counseled that they might develop mental health problems. Now a new study, considered to be the most rigorous to look at the question in the United States, undermines that claim.

December 14, 2016 9:00 am

Endgame in Aleppo, the most decisive battle yet in Syria’s war (Washington Post)

Aleppo would go down in history as one of the great failures of the international community to halt human rights abuses.

View More News Items